Calibrant’s Gemini proteomics discovery technology will be used.
Calibrant Biosystems and Yale University School of Medicine will work together to identify ovarian and breast cancer drug targets. Under this research collaboration, Calibrant’s Gemini proteomics platform will be used on tissue specimens to discover relevant proteins and protein networks involved in disease progression.
Gemini™ enables quantitative protein profiling of isolated and homogeneous cell populations from fresh and formalin-fixed tissues. Sample requirements are matched to microdissection methods and coupled with an integrated bioinformatics suite.
“Our collaboration with Dr. Tavasolli at Yale University contributes substantially to our gynecologic and breast cancer drug programs,” notes Brian Balgley, Ph.D., CTO.
